Compugen (NASDAQ:CGEN) Posts Quarterly Earnings Results

Compugen (NASDAQ:CGEN) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01), FiscalAI reports. The business had revenue of $2.18 million for the quarter, compared to analysts’ expectations of $1.57 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%.

Compugen Stock Performance

Shares of Compugen stock opened at $2.75 on Monday. Compugen has a 52-week low of $1.29 and a 52-week high of $3.23. The stock has a market capitalization of $260.01 million, a price-to-earnings ratio of 7.43 and a beta of 2.79. The company’s 50 day moving average price is $2.49 and its 200-day moving average price is $1.99.

Wall Street Analysts Forecast Growth

Several research firms have commented on CGEN. Truist Financial raised shares of Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Finally, Lake Street Capital assumed coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Compugen has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in shares of Compugen in the fourth quarter worth approximately $104,000. Security National Bank of Sioux City Iowa IA bought a new position in shares of Compugen in the fourth quarter worth approximately $38,000. Marshall Wace LLP grew its holdings in shares of Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 61,202 shares during the last quarter. State Street Corp lifted its stake in Compugen by 3.9% in the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after acquiring an additional 14,701 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock worth $2,229,000 after acquiring an additional 51,565 shares during the period. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.